March 30, 2017
Bristol-Myers Squibb Company and Foundation Medicine has announced a collaboration that leverages comprehensive genomic profiling and molecular information solutions of Foundation Medicine to identify predictive biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating cancer immunotherapies of Bristol-Myers Squibb. Biomarkers can be used to characterize a tumor and the tumor microenvironment, which may reveal immune-related mechanisms that predict how a patient may respond to immunotherapy.
Fouad Namouni, M.D., head of Development, Oncology, Bristol-Myers Squibb, said: “Translational medicine research is critical to further our understanding of cancer biology and to identify which patient populations are most likely to derive benefit from our Immuno-Oncology agents. We believe this collaboration with Foundation Medicine will help us better understand the relation of genomic approaches to immunotherapy efficacy across a number of different tumor types and immunotherapy agents.”
“Cancer immunotherapy is evolving rapidly, and biopharmaceutical companies and practicing oncologists alike may benefit from a reliable, validated, comprehensive view of mutational burden and genomic alterations to make the most informed care decisions. Our collaboration with Bristol-Myers Squibb highlights the potential value of our molecular information platform to the biopharma industry for its ability to inform, to reduce risk and to accelerate clinical development in this high growth and highly competitive oncology field,” said Melanie Nallicheri, chief business officer and head, Biopharma for Foundation Medicine.Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agentslast edit: 2017-04-07T15:03:08+00:00da